Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties

O Penack, G Tridello, J Hoek, G Socie, D Blaise, J Passweg, P Chevallier, C Craddock, N Milpied, H Veelken, J Maertens, P Ljungman, Jan Cornelissen, A Thiebaut-Bertrand, B Lioure, M Michallet, S Iacobelli, A Nagler, M Mohty, S Cesaro

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)


Historically, invasive aspergillosis (IA) has been a major barrier for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The influence of invasive IA on long-term survival and on transplant-related complications has not been investigated in a larger patient cohort under current conditions. Our aim was to analyze the long-term outcome of patients undergoing allo-HSCT with a history of prior IA. We used European Society for Blood and Marrow Transplantation database data of first allo-HSCTs performed between 2005 and 2010 in patients with acute leukemia. One thousand one hundred and fifty patients with data on IA before allo-HSCT were included in the analysis. The median follow-up time was 52.1 months. We found no significant impact of IA on major transplant outcome variables such as overall survival, relapse-free survival, non-relapse mortality, cumulative incidence of acute GvHD grade II-IV, chronic GvHD, pulmonary complications and leukemia relapse. However, we found a trend toward lower overall survival (P = 0.078, hazard ratio (HR) (95% confidence interval (CI)): 1.16 (0.98, 1.36)) and higher non-relapse mortality (P = 0.150, HR (95% CI): 1.19 (0.94, 1.50)) in allo-HSCT recipients with pre-existing IA. Our data suggest that a history of IA should not generally be a contraindication when considering the performance of allo-HSCT in patients with acute leukemia.
Original languageUndefined/Unknown
Pages (from-to)418-423
Number of pages6
JournalBone Marrow Transplantation
Issue number3
Publication statusPublished - 2016

Research programs

  • EMC MM-02-41-04

Cite this